New research suggests that patients who come off popular GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Published data in a leading medical journal points out that while obese individuals often shed a large proportion of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month after stopping.
"Users buying such drugs should be cognizant of the danger of quick rebound weight gain when the medication is stopped," stated researcher Dr. Susan Jebb.
This pace of regain means a reversion to original weight in about one and a half years.
Comparing Therapies
The analysis, which looked at 37 of trials involving over 9,000 of participants, compared the results of these new drugs with older methods.
The team emphasize that people who lose weight through lifestyle changes alone usually experience a slower weight regain—approximately 100 grams monthly—after stopping.
Explaining the Rapid Rebound
Nutrition scientists propose the way of the jabs explains the amplified weight return.
The injections mimic a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the body to produce less of its endogenous hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement means appetite is unsuppressed, making excessive eating much more probable."
A Lifelong Disease?
The NHS suggest the injections for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Many experts say that, due to the significant potential of relapse, the therapy might need to be life-long.
This view is reinforced by drug manufacturers, who note that the results "emphasize the chronic nature of obesity," akin to managing diseases like hypertension.
Patient Accounts
Users who have discontinued the medication report a sudden resurgence of appetite.
"It was like something activating and you're instantly starving," described one woman.
The struggle is exacerbated if patients have not developed lasting dietary or behavioural changes during therapy.
Significant Use
Survey data suggest that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is higher among women than males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Ultimately, experts emphasize that while these medications are potent tools for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on integrated behavioural support.
